Subscribe to be the first to know about Best Deals and Exclusive Offers!
JOURNAL TITLE: AMEI's Current Trends in Diagnosis & Treatment
Erlotinib is a reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, competitively inhibiting adenosine triphosphate (ATP) binding at the active site of the kinase. It is approved for treatment of advanced and metastatic cancers. The objective of this report is to find out the cause of the papulopustular lesion while the patient is on tyrosine kinase inhibitor. Our 57-year-old male known case of metastatic pancreatic cancer is on injection gemcitabine 1400 mg (D1 and D8), injection carboplatin 450 mg (D1), and tablet erlotinib 150 mg OD since 1.5 months and after 3 weeks of therapy he developed papulopustular lesions over legs and face which is a side effect of tablet erlotinib and thus it is discontinued and now the patient is being treated for papulopustular lesion by oral and topical antibiotics.
© 2019 Jaypee Brothers Medical Publishers (P) LTD. | All Rights Reserved